NuVasive still expects 2023 net sales growth 6%-8%, revenue consensus $1.29B
PremiumThe FlyNuVasive still expects 2023 net sales growth 6%-8%, revenue consensus $1.29B
1y ago
NuVasive reports Q2 non-GAAP EPS 56c, consensus 55c
Premium
The Fly
NuVasive reports Q2 non-GAAP EPS 56c, consensus 55c
1y ago
NuVasive price target raised to $51 from $48 at Truist
Premium
The Fly
NuVasive price target raised to $51 from $48 at Truist
1y ago
TD Cowen medical devices analyst to hold analyst/industry conference call
PremiumThe FlyTD Cowen medical devices analyst to hold analyst/industry conference call
2y ago
TD Cowen medical devices analyst to hold analyst/industry conference call
Premium
The Fly
TD Cowen medical devices analyst to hold analyst/industry conference call
2y ago
NuVasive says ISS recommends vote in favor of Globus deal
Premium
The Fly
NuVasive says ISS recommends vote in favor of Globus deal
2y ago
Canaccord upgrades Globus Medical with merger uncertainty priced in
PremiumThe FlyCanaccord upgrades Globus Medical with merger uncertainty priced in
2y ago
NuVasive gets FDA 510(k) clearance for Precice limb lengthening solution
Premium
The Fly
NuVasive gets FDA 510(k) clearance for Precice limb lengthening solution
2y ago
NuVasive reports Q4 non-GAAP EPS 43c, consensus 51c
Premium
The Fly
NuVasive reports Q4 non-GAAP EPS 43c, consensus 51c
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100